tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VTGN Stock Latest News

VistaGen updates corporate presentation highlighting neuroscience pipeline
Company AnnouncementsVistaGen updates corporate presentation highlighting neuroscience pipeline
8h ago
8K
VTGN
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
PremiumCompany Announcements
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
18d ago
8K
VTGN
Vistagen downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Vistagen downgraded to Hold from Buy at Jefferies
23d ago
VTGN
Vistagen downgraded to Hold at Jefferies after social anxiety study miss
PremiumThe Fly
Vistagen downgraded to Hold at Jefferies after social anxiety study miss
23d ago
VTGN
Vistagen downgraded to Hold from Buy at Maxim
PremiumThe Fly
Vistagen downgraded to Hold from Buy at Maxim
24d ago
VTGN
Vistagen downgraded to Market Perform from Outperform at William Blair
PremiumThe FlyVistagen downgraded to Market Perform from Outperform at William Blair
24d ago
VTGN
Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss
Premium
The Fly
Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss
24d ago
VTGN
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
Premium
The Fly
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
24d ago
VTGN
Vistagen downgraded to Hold from Buy at Stifel
PremiumThe Fly
Vistagen downgraded to Hold from Buy at Stifel
24d ago
VTGN
Vistagen downgraded to Neutral from Buy at Lucid Capital
PremiumThe Fly
Vistagen downgraded to Neutral from Buy at Lucid Capital
24d ago
VTGN
Vistagen SAD study did not achieve primary endpoint
PremiumThe Fly
Vistagen SAD study did not achieve primary endpoint
24d ago
VTGN
VistaGen Therapeutics trading resumes
PremiumThe Fly
VistaGen Therapeutics trading resumes
24d ago
VTGN
VistaGen Therapeutics trading halted, news pending
PremiumThe FlyVistaGen Therapeutics trading halted, news pending
24d ago
VTGN
VistaGen Therapeutics Appoints New CFO Nick B. Tressler
Premium
Company Announcements
VistaGen Therapeutics Appoints New CFO Nick B. Tressler
1M ago
8K
VTGN
Vistagen names Nick Tressler CFO
Premium
The Fly
Vistagen names Nick Tressler CFO
1M ago
VTGN
Vistagen presents exploratory PH80 data at Menopause Society meeting
PremiumThe Fly
Vistagen presents exploratory PH80 data at Menopause Society meeting
1M ago
VTGN
VistaGen Therapeutics: Buy Rating Backed by Promising Clinical Trials and Stable Financial Outlook
PremiumRatings
VistaGen Therapeutics: Buy Rating Backed by Promising Clinical Trials and Stable Financial Outlook
2M ago
VTGN
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges
2M ago
VTGN
Vistagen Therapeutics Reports Q2 2026 Financial Results
PremiumCompany Announcements
Vistagen Therapeutics Reports Q2 2026 Financial Results
2M ago
VTGN
VistaGen Therapeutics: Buy Rating Affirmed Amid Promising Fasedienol Trials and Market Potential
PremiumRatingsVistaGen Therapeutics: Buy Rating Affirmed Amid Promising Fasedienol Trials and Market Potential
2M ago
VTGN
Vistagen reports Q2 EPS (54c), consensus (44c)
Premium
The Fly
Vistagen reports Q2 EPS (54c), consensus (44c)
2M ago
VTGN
VistaGen Completes Patient Phase in Key Clinical Trial
Premium
Company Announcements
VistaGen Completes Patient Phase in Key Clinical Trial
2M ago
8K
VTGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >